Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

April W. Armstrong; C. Paul; L. Puig; Wolf‐­Henning Boehncke; Michael L. Freeman; Hideshi Torii; Kim Papp; Christopher Em Griffiths; Andrew Blauvelt; Kristian Reich; Melinda Gooderham; Tadashi Terui; L. Renda; Noah Agada; Wen Xu; Gaia Gallo; Mark Lebwohl

doi:10.1007/s13555-019-00340-3

Back

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

Article 2019 en

Related publications

Article2006

USE OF SOFA SCORES TO UNDERSTAND DEATH IN SEVERE SEPSIS PATIENTS: RESULTS FROM THE INDEPTH DATABASE.

Jean Louis Vincent, Mark D. Williams, David R. Nelson

Article2022

Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure

Christopher Em Griffiths, Melinda Gooderham, Jean‐Frédéric Colombel, Tadashi Terui, Ana P. Accioly, Gaia Gallo, Danting Zhu, Andrew Blauvelt

Article2022

32236 Safety of ixekizumab in adult patients with moderate-to-severe psoriasis: Data from 15 clinical trials with over 18,000 patient-years of exposure

Christopher Em Griffiths, Melinda Gooderham, Jean‐Frédéric Colombel, Tadashi Terui, Ana P. Accioly, Gaia Gallo, Danting Zhu, Andrew Blauvelt

Article2013

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

Kim Papp, Christopher Em Griffiths, Kenneth B. Gordon, Mark Lebwohl, Philippe Szapary, Yasmine Wasfi, Daphne Chan, M.-C. Hsu, Vincent Ho, Pierre‐Dominique Ghislain, Bruce Strober, Kristian Reich

Article2019

Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)

Andrew X. Zhu, Peter R. Galle, Josep M. Llovet, Richard S. Finn, Yoon‐Koo Kang, Chung‐Jen Yen, Éric Assenat, Giovanni Brandi, Kenta Motomura, Izumi Ohno, Bruno Daniele, Arndt Vogel, Tatsuya Yamashita, Chih‐Hung Hsu, Tim Meyer, Ryan C. Widau, William R. Schelman, C. Wang, Yanzhi Hsu, Masatoshi Kudo

Annals of Oncology

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

Abstract

Discussion(0)

Related publications

USE OF SOFA SCORES TO UNDERSTAND DEATH IN SEVERE SEPSIS PATIENTS: RESULTS FROM THE INDEPTH DATABASE.

Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure

32236 Safety of ixekizumab in adult patients with moderate-to-severe psoriasis: Data from 15 clinical trials with over 18,000 patient-years of exposure

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)